Evoke Pharma Stock Fundamentals
| EVOK Stock | USD 0.45 0 0.22% |
Evoke Pharma fundamentals help investors to digest information that contributes to Evoke Pharma's financial success or failures. It also enables traders to predict the movement of Evoke Stock. The fundamental analysis module provides a way to measure Evoke Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evoke Pharma stock.
At this time, Evoke Pharma's Non Operating Income Net Other is quite stable compared to the past year. Evoke | Select Account or Indicator |
Evoke Pharma Company Operating Margin Analysis
Evoke Pharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Evoke Pharma Operating Margin | (1.13) % |
Most of Evoke Pharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evoke Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Evoke Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Evoke Pharma has an Operating Margin of -1.1265%. This is 96.79% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The operating margin for all United States stocks is 79.56% lower than that of the firm.
Evoke Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evoke Pharma's current stock value. Our valuation model uses many indicators to compare Evoke Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evoke Pharma competition to find correlations between indicators driving Evoke Pharma's intrinsic value. More Info.Evoke Pharma is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, Evoke Pharma's Return On Equity is quite stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Evoke Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Evoke Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evoke Pharma's earnings, one of the primary drivers of an investment's value.Evoke Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evoke Pharma's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evoke Pharma could also be used in its relative valuation, which is a method of valuing Evoke Pharma by comparing valuation metrics of similar companies.Evoke Pharma is currently under evaluation in operating margin category among related companies.
Evoke Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evoke Pharma from analyzing Evoke Pharma's financial statements. These drivers represent accounts that assess Evoke Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evoke Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 36.1M | 65.8M | 17.7M | 8.4M | 3.5M | 3.3M | |
| Enterprise Value | 30.6M | 62.9M | 13.6M | 3.7M | 3.8M | 3.6M |
Evoke Fundamentals
| Return On Equity | -10.35 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (1.50) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 4.25 M | ||||
| Shares Outstanding | 8.6 M | ||||
| Shares Owned By Insiders | 9.64 % | ||||
| Shares Owned By Institutions | 34.70 % | ||||
| Number Of Shares Shorted | 38.42 K | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 0.83 X | ||||
| Revenue | 5.18 M | ||||
| Gross Profit | 2.14 M | ||||
| EBITDA | (7.43 M) | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 4.02 X | ||||
| Total Debt | 5 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 10.65 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (4.98 M) | ||||
| Short Ratio | 1.74 X | ||||
| Earnings Per Share | (2.33) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 7.0 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 4.04 M | ||||
| Total Asset | 7.07 M | ||||
| Retained Earnings | (123.44 M) | ||||
| Working Capital | 3.79 M | ||||
| Current Asset | 9.52 M | ||||
| Current Liabilities | 1.83 M | ||||
| Net Asset | 7.07 M |
About Evoke Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evoke Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evoke Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evoke Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -4.5 M | -4.7 M | |
| Total Revenue | 5.2 M | 5.4 M | |
| Cost Of Revenue | 201.9 K | 108.6 K | |
| Stock Based Compensation To Revenue | 0.22 | 0.21 | |
| Sales General And Administrative To Revenue | 0.00 | 0.00 | |
| Research And Ddevelopement To Revenue | 0.04 | 0.03 | |
| Capex To Revenue | 0.00 | 0.00 | |
| Revenue Per Share | 1.55 | 1.63 | |
| Ebit Per Revenue | (1.43) | (1.51) |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Evoke Pharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Evoke Pharma Piotroski F Score and Evoke Pharma Altman Z Score analysis. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Evoke Stock analysis
When running Evoke Pharma's price analysis, check to measure Evoke Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evoke Pharma is operating at the current time. Most of Evoke Pharma's value examination focuses on studying past and present price action to predict the probability of Evoke Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evoke Pharma's price. Additionally, you may evaluate how the addition of Evoke Pharma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Evoke Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 1.55 | Quarterly Revenue Growth 1.105 | Return On Assets (0.49) | Return On Equity (10.35) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.